Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of Rezurock plus prednisone versus placebo plus prednisone in newly diagnosed chronic graft-versus-host disease
MOH_2024-01-15_013118Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Rezurock + prednisone with Placebo + prednisone (2 arms). Started Nov 2023; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2024-01-15_013118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-15_013118.